8-K: Telomir Pharmaceuticals Changes Auditors Following Resignation of Cherry Bekaert LLP

Telomir Pharmaceuticals has announced the resignation of its independent auditor, Cherry Bekaert LLP, and the engagement of Salberg & Company P.A. as its new auditor.

Summary

• Telomir Pharmaceuticals' independent auditor, Cherry Bekaert LLP, resigned on December 16, 2024.
• Cherry Bekaert's reports for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or disclaimer, but included an explanatory paragraph about the company's ability to continue as a going concern.
• There were no disagreements between Telomir and Cherry Bekaert on accounting principles, financial statement disclosure, or auditing scope.
• Cherry Bekaert did advise the company of material weaknesses in its internal control over financial reporting as of December 30, 2023 and 2022.
• On December 18, 2024, Telomir engaged Salberg & Company P.A. as its new independent auditor for the fiscal year ending December 31, 2024.
• Telomir did not consult with Salberg prior to their engagement on any accounting, auditing, or financial reporting issues.

Sentiment

Score: 3

Explanation: The resignation of the auditor, coupled with the disclosure of material weaknesses in internal controls and a going concern paragraph, suggests significant issues and raises concerns about the company's financial health and reporting practices.

Positives

• The transition to a new auditor was completed quickly, with Salberg & Company P.A. engaged just two days after Cherry Bekaert's resignation.
• Cherry Bekaert confirmed that there were no disagreements with Telomir on accounting or auditing matters.

Negatives

• Cherry Bekaert identified material weaknesses in Telomir's internal control over financial reporting for both 2023 and 2022.
• Cherry Bekaert's reports included an explanatory paragraph regarding the company's ability to continue as a going concern.

Risks

• The change in auditors could potentially lead to increased scrutiny of Telomir's financial statements.
• The identified material weaknesses in internal controls could indicate potential issues with the reliability of financial reporting.
• The going concern paragraph in the previous auditor's report raises concerns about the company's financial stability.

Management Comments

• The Audit Committee recommended the engagement of Salberg & Company P.A. as the new auditor.
• The Board of Directors approved the engagement of Salberg & Company P.A.

Industry Context

Changes in auditors are not uncommon, but the circumstances surrounding the resignation, including the material weaknesses in internal controls and the going concern paragraph, may raise concerns among investors and stakeholders.

Comparison to Industry Standards

• The resignation of an auditor is not unusual, but the presence of material weaknesses in internal controls is a concern that would be viewed negatively by investors.
• The inclusion of a going concern paragraph in the audit report is a significant issue that would be viewed negatively by investors and is not typical for a company listed on the Nasdaq Capital Market.
• Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX) have faced scrutiny over their financial reporting and internal controls, highlighting the importance of robust auditing practices.

Stakeholder Impact

• Shareholders may be concerned about the change in auditors and the identified weaknesses in internal controls.
• Creditors may be more cautious about extending credit to the company given the going concern paragraph in the previous audit report.
• Employees may be concerned about the company's financial stability.

Next Steps

• Salberg & Company P.A. will conduct the audit for the fiscal year ending December 31, 2024.
• Telomir will need to address the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

auditor, accounting, financial reporting, internal control, resignation, engagement, Cherry Bekaert, Salberg & Company, material weakness